Matt During

Matthew During is an MIT, Harvard, and Yale-trained M.D., Ph.D. neuroscientist and serial biotechnology entrepreneur originally from New Zealand. He served 9 years on the faculty of Yale as a Professor of Neurosurgery.

Subsequently, Dr. During served as a Professor at Thomas Jefferson, Cornell, and Ohio State Universities and a senior manager at Bridgewater Associates, and over the past 10 years, he continues as a visiting Professor of Translational Neuroscience at the University of Oxford. He was a pioneer in the use of viral vectors for neurological disorders and was the first to carry out gene transfer into the brain of a human child.

Dr. During was the Principal Investigator and the FDA sponsor for two pioneering gene therapy studies on neurodevelopmental and movement disorders. He has published over 250 scientific articles, with many in the world’s most prestigious journals including Nature, Science, Cell, Nature Medicine, Nature Genetics, the Lancet, and Science Translational Medicine. He is the inventor of 52 issued US patents.

In addition, he has won several awards including the American Epilepsy Society Young Investigator of the Year, Roche Translational Neuroscience Award, Johnson and Johnson Focused Giving Award, BMS Neuroscience Award, the Nancy Sirrett, and Keith Harrison Awards. He is a Fellow of the American College of Physicians, the Royal Australasian College of Physicians, and a Fellow of the American Association for the Advancement of Science.

He was a co-founder of Merlin Pharmaceuticals, Neurologix, Vector Neurosciences, Emrys Bio, and Nightstar Therapeutics, and founder of Ovid Therapeutics where he previously served as President, Chief Scientific Officer, and chair of the Scientific Advisory Board.